Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

AmbiJet AmbiJet: the world’s first and only highly effective plasma-based solution for Europe’s 16 Million periimplantitis patients urgently needing help to avoid losing their dental implant

Coordinator
Freiburger Medizintechnik GmbH, Germany
Runs
1 October 2022 to 30 September 2025
Status
Running
EU funding
€1.4m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190173644

What the project is doing

In the project's own words, from its summary on CORDIS.

Regular dental check-ups and treatments not only ensure a beautiful smile, but good general health: a healthy oral cavity strengthens the immune system and acts as a barrier against various heart-, kidney-, or lungs-related diseases and diabetes. There is currently no effective solution to treat the 16.3 mn infected dental implants (EU, 2019). Freiburger Medizintechnik GmbH developed the solution dentists are looking for: a disruptive technology for highly effective infection control to fight periimplantitis.

AmbiJet® is the world’s first and only plasma-based technology with the ability to kill bacteria on dental implants in-situ. It disrupts the status-quo of medical technologies by preventing the reinfection of disinfected surfaces and shows maximum effectiveness without side nor adverse effects: pharmacological and chemical substances are no longer required. AmbiJet® reduces inflammation, saves dental implants and helps patients live a healthier life.

Topics

Who is involved

OrganisationCityCountryRole
Freiburger Medizintechnik GmbHFreiburgGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI